Clinical Trial Update: Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

View source ↗

Summary

This clinical trial update examines the safety and potential efficacy of administering the influenza vaccine at the same time as anti-PD-1 therapies (nivolumab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancy

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• OPDIVO (nivolumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Influenza Virus Vaccine Adverse Reaction (Disorder), Influenza | Status: COMPLETED